AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MedLife S.A.

Report Publication Announcement Jan 27, 2025

2292_iss_2025-01-27_38aee5f0-eb0e-4871-9e7a-aae83b0490f0.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

To: BUCHAREST STOCK EXCHANGE FINANCIAL SUPERVISORY AUTHORITY

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 24/2017 on issuers of financial instruments and market operations, and the provisions of Article 99 of the Bucharest Stock Exchange Code, Title II, Issuers and Financial Instruments

Report Date: 27 January 2025

Name of the issuing company: MED LIFE S.A. ("MedLife" or "the Company") Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania Telephone / Fax number: 0374 180 470 Unique Registration Code at the National Office of Trade Registry: 8422035 Order number on the Trade Registry: J40/3709/1996 Subscribed and paid-in share capital: 132,870,492 RON Total number of shares: 531,481,968 (out of which 427,042 shares without voting rights and 531,054,926 shares with voting rights) Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Premium Category

Significant events to report:

Closed trading period: 29 January – 27 February 2025

MED LIFE S.A. informs investors that between 29 January and 27 February 2025, the persons who have access to privileged information ("insiders") according to the provisions of FSA Regulation no. 5/2018, Law no. 24/2017 and EU Regulations no. 522/2016 and no. 596/2014 respectively, do not have the right to carry out any transactions in their own name or on behalf of a third party, directly or indirectly, related to shares, bonds, securities, debt or other derivative financial instruments of the Company.

This closed trading period occures as a result of the fact that on 28 February 2025, the Company will publish the 2024 Unaudited Preliminary Annual Financial Results.

Mihail Marcu Chief Executive Officer

______________

Talk to a Data Expert

Have a question? We'll get back to you promptly.